OPR - Delayed Quote • USD DAWN Jul 2024 17.500 call (DAWN240719C00017500) Follow 1.6000 +0.7500 (+88.24%) At close: April 26 at 3:34 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for DAWN240719C00017500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: DAWN Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor Companies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growth 13 Best Biotech Stocks To Buy Under $20 Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress Dwayne 'The Rock' Johnson's net worth: How the new TKO Board Member built his wealth from $7 Day One Announces Two New Appointments to Board of Directors Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate Progress Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
